Articles from Revance Therapeutics, Inc.

Crown Laboratories, Inc. (“Crown”) and Revance Therapeutics, Inc. (NASDAQRVNC) (“Revance”), today announced that, on January 17, 2025, they amended their previously announced Amended and Restated Merger Agreement (the “Second Amendment,” together with the Amended and Restated Merger Agreement, dated December 7, 2024, the “A&R Merger Agreement”).

Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQRVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings, today announced that they have amended and restated the merger agreement entered into by the parties on August 11, 2024, pursuant to which the companies will seek to merge the two organizations. Under the terms of the amended and restated merger agreement, which has been unanimously approved by Revance’s Board of Directors, Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $3.10 per share in cash.

Revance Therapeutics, Inc. (NASDAQRVNC) (“Revance,” the “Company” or “our”), today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update.

Revance Therapeutics, Inc. (NASDAQRVNC), today reported financial results for the second quarter ended June 30, 2024 and provided a corporate update.

Revance Therapeutics, Inc. (NASDAQRVNC) today announced that the company will release second quarter 2024 financial results on Thursday, August 8, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced new hire grants totaling an aggregate of 104,800 inducement restricted stock units (“RSUs”) to 31 employees. The RSUs vest over four years, with 25% of the underlying shares vesting on each of the four anniversaries of the applicable vesting commencement date, subject to the new employee's continued service relationship with Revance through the applicable vesting dates.

Revance Therapeutics, Inc. (NASDAQRVNC) today announced that the company will be participating in the following investor conferences.

Revance Therapeutics, Inc. (NASDAQRVNC), today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Revance Therapeutics, Inc. (NASDAQRVNC), today announced the commercial launch of DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia, providing patients and physicians with a compelling new treatment option for a painful and disabling chronic condition. The launch marks Revance’s entry into the large and growing U.S. therapeutics neurotoxin market.

Revance Therapeutics, Inc. (NASDAQRVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Revance Therapeutics, Inc. (NASDAQRVNC), today announced two poster presentations on DAXXIFY® for the treatment of cervical dystonia at the annual meeting of American Academy of Neurology (AAN), taking place April 13-18, 2024, in Denver, Colorado.

Revance Therapeutics, Inc. (NASDAQRVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units (“RSUs”) to 29 employees. The RSUs vest over four years, with 25% of the underlying shares vesting on each of the four anniversaries of the applicable vesting commencement date, subject to the new employee's continued service relationship with Revance through the applicable vesting dates.

Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $6.25 per share. The gross proceeds from the public offering are expected to be $100.0 million, before deducting underwriting discounts and commissions and other offering expenses. The public offering is expected to close on or about March 6, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to advance the commercial growth of its aesthetics portfolio, including DAXXIFY® and the RHA® Collection of dermal fillers, support the launch of DAXXIFY® into the therapeutics market, as well as for working capital, research and development and general corporate purposes.

Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced a proposed underwritten public offering of $100 million of its common stock. In addition, the Company expects to grant the underwriter a 30-day option to purchase additional shares in an amount not to exceed 15% of the number of shares of common stock offered in the public offering. The Company intends to use the net proceeds from the offering to advance the commercial growth of its aesthetics portfolio, including DAXXIFY® and the RHA® Collection of dermal fillers, support the launch of DAXXIFY® into the therapeutics market, as well as for working capital, research and development and general corporate purposes. The offering is subject to prevailing market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Revance Therapeutics, Inc. (NASDAQRVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Revance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences.

Revance Therapeutics, Inc. (RVNC) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code (J0589) for DAXXIFY®, indicated for the treatment of cervical dystonia in adults. J-Codes are product-specific reimbursement codes used by commercial insurance plans, Medicare, and other government payers and are intended to simplify reimbursement for providers and expand access for patients.

Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference, taking place February 7-8, 2024, in New York, New York. Chief Executive Officer, Mark J. Foley, is scheduled to participate in a fireside chat on Thursday, February 8, at 9:30a.m. EST.

Revance Therapeutics, Inc. (NASDAQRVNC) today provided a corporate update as well as preliminary unaudited fourth quarter and full year 2023 financial results, 2024 guidance and financial outlook. A supplemental presentation can also be found on the company’s investor relations website.

Revance Therapeutics, Inc. (RVNC), today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced the appointment of Erica Jordan, Senior Vice President of Commercial to Chief Commercial Officer (CCO), Aesthetics. As CCO, Erica will have global responsibility for all aesthetics commercial activity including commercial strategy, sales and marketing, branding, loyalty and engagement.

Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the following investor conferences.

Revance Therapeutics, Inc. (RVNC) today announced that the company will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

TIME® has unveiled its annual Best Inventions list, which features 200 of the year’s best innovations that are making the world better, smarter, and more enjoyable.

Revance Therapeutics, Inc. (RVNC) announced that the company is hosting its Investor Day today, September 19, 2023, from 9:30 am ET to 12:00 pm ET.

Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the company will host an Investor Day on September 19, 2023, from 9:30 AM ET to 1:00 PM ET.

Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved the first therapeutic indication for DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults.7 DAXXIFY®, powered by Peptide Exchange Technology™, was previously approved by the FDA for the temporary improvement of glabellar lines (frown lines) in adults in September 2022 and is the first true innovation in neuromodulator product formulation in more than 30 years.8-11

Revance Therapeutics, Inc. (RVNC), today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Revance Therapeutics, Inc. (RVNC), today announced that the company will release second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Revance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences.

Revance Therapeutics, Inc. (RVNC), today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Revance Therapeutics, Inc. (RVNC), today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced that the company will participate in the 22nd Annual Needham Virtual Healthcare Conference, taking place April 17 – 20, 2023. Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Tuesday, April 18, at 12:45 P.M. ET.

Revance Therapeutics, Inc. (RVNC), today announced the release of its 2022 ESG Report, detailing the company’s progress towards its ESG priorities of innovation and access, workplace culture and strong corporate governance. The report was guided by the Sustainability Accounting Standards Board (SASB) framework.

Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the following investor conferences.

Revance Therapeutics, Inc. (RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Revance Therapeutics, Inc. (RVNC), announced today the appointment of Dr. Vlad Coric, M.D., to its Board of Directors, effective March 1, 2023. Dr. Coric brings more than 22 years of drug development and executive leadership experience to Revance based on his time at the Yale School of Medicine, Bristol-Myers Squibb, and Biohaven, which was acquired by Pfizer in 2022. The company also announced that long-standing director Philip Vickers has decided that he will be retiring from the Board effective immediately prior to the company’s 2023 Annual Meeting of Stockholders.

Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the 43rd Annual Cowen Healthcare Conference, taking place March 6-8, 2023, in Boston, Massachusetts.

Revance Therapeutics, Inc. (RVNC) today announced that new data on DAXXIFY® will be presented at the annual meeting of Association of Academic Physiatrists (AAP), taking place in Anaheim, California, February 21-24, 2023. The supplemental biologics license agreement for DAXXIFY® for the treatment of cervical dystonia is currently under regulatory review with the Food and Drug Administration.

Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.

Revance Therapeutics, Inc. (RVNC) today provided an update on its early experience program for DAXXIFY® and its preliminary unaudited fourth quarter and full year 2022 financial results.

Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults, a chronic and debilitating neurologic condition affecting the muscles of the neck.1 Revance was provided a Prescription Drug User Fee Act (PDUFA) date of August 19, 2023.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 34th Annual Piper Sandler Healthcare Conference, taking place November 29-December 1, 2022, in New York City. Chief Executive Officer, Mark J. Foley, is scheduled to present on Tuesday, November 29, at 10:00AM ET.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Stifel 2022 Healthcare Conference, taking place November 15-16, 2022, in New York City. Chief Financial Officer, Tobin Schilke, is scheduled to present on Tuesday, November 15, at 3:00 p.m. ET.

Revance Therapeutics, Inc. (Nasdaq: RVNC), today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial-stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the publication of two peer-reviewed articles in the Aesthetic Surgery Journal, the official journal of The Aesthetic Society. The publications highlight the nuances of glabellar line (GL) injection technique and aim to improve patient outcomes, irrespective of the neuromodulator used. The first publication demonstrates the impact of subtle variations in glabellar line injection technique on eyebrow position, and the second proposes a structured and comprehensive assessment algorithm focused on anatomical principles, allowing for an individualized treatment approach.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release third quarter 2022 financial results on Tuesday, November 8, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.

Revance Therapeutics, Inc. (Nasdaq: RVNC) a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for DAXXIFY™ for the treatment of cervical dystonia. Cervical dystonia is a painful and disabling chronic condition in which the neck muscles contract involuntarily, causing abnormal movements and awkward posture of the head and neck.1

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the appointment of David A. Hollander, M.D., M.B.A., as Chief Medical Officer to lead clinical development, data science, medical affairs, scientific innovation, pharmacovigilance and regulatory affairs.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced today it will present two video abstracts featuring DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection at the American Society for Dermatologic Surgery (ASDS) Annual Meeting taking place in Aurora, CO, from October 6-10, 2022.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Guggenheim Nantucket Therapeutics Conference, taking place September 27 – 29, in Nantucket, MA.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the publication of two peer-reviewed articles in Aesthetic Surgery Journal, the official journal of The Aesthetic Society. The publications reported the impact of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection on brow position and frontalis muscle activity from a post-hoc analysis of patients in the Phase 2a forehead line (FHL) study and the SAKURA open-label safety (OLS) study as well as presenting the efficacy and safety of DAXXIFY™ analyzed by age and race based on a subgroup analysis of the SAKURA glabellar lines clinical trials.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced an oral presentation by Dr. Atul Patel, JUNIPER clinical investigator, will take place on Friday, September 16 at 2:30 pm GMT+ 2 at the International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in Madrid, Spain. The presentation will include results from Revance’s JUNIPER Phase 2 clinical trial evaluating the efficacy and safety of three doses of DAXXIFY™ compared to placebo for adults with upper limb spasticity (ULS) after stroke or traumatic brain injury.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,200,000 additional shares, at a price to the public of $25.00 per share. All of the shares were offered by Revance. The aggregate gross proceeds from the public offering were $230.0 million, before deducting underwriting discounts and commissions and other offering expenses.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced the pricing of an upsized underwritten public offering of 8,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $25.00 per share. All of the shares are being offered by Revance. The gross proceeds from the public offering are expected to be $200.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Revance has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on or about September 15, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund the commercialization of DAXXIFY™, the RHA® Collection of dermal fillers and OPUL®, and for working capital, research and development and general corporate purposes.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced a proposed underwritten public offering of $150 million of its common stock. In addition, Revance expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. The Company intends to use the net proceeds from the offering to fund the commercialization of DAXXIFY™, the RHA® Collection of dermal fillers and OPUL®, and for working capital, research and development and general corporate purposes. The offering is subject to prevailing market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults.1 DAXXIFY™ is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum albumin and animal-based components.1-2,7-11 Most importantly, DAXXIFY™ has the ability to address duration of treatment effect, which we believe is the greatest unmet need with existing neuromodulators for both consumers and injectors.12 The FDA approval, Revance’s first, augments the company’s innovative aesthetics portfolio and expands the company’s access to the growing $3.2 billion U.S. facial injectables market, further establishing Revance as an innovation leader in the industry and laying the groundwork for potential future therapeutic indications.13

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the presentation of six abstracts to be presented at the 2022 TOXINS International Conference on July 27-30, 2022 in New Orleans, Louisiana.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the William Blair 42nd Annual Growth Stock Conference, taking place June 6-9, in Chicago. Chief Executive Officer, Mark Foley, is scheduled to present on Monday, June 6, at 2:00 p.m. CT / 3:00 p.m. ET.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release first quarter financial results on Tuesday, May 10, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced they will give one oral presentation and present one poster at the 2022 American Academy of Neurology Annual Meeting, taking place on April 2-7, 2022 in Seattle, Washington.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the closing of a $300 million note purchase agreement with funds managed by Athyrium Capital Management, LP, a leading healthcare-focused investment firm.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release fourth quarter and full year 2021 financial results on Monday, February 28, 2022 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, announced today that it has received the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for DaxibotulinumtoxinA for Injection for glabellar lines. The Type A meeting was held on December 15, 2021.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today provided preliminary fourth quarter and full year 2021 financial results and a corporate update.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced two oral presentations and one ePoster at the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, November 19-21, 2021.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s Chief Executive Officer, Mark Foley, and Chief Financial Officer, Tobin Schilke, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Stifel 2021 Virtual Healthcare Conference, a fully virtual management access conference, taking place November 15-17.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release third quarter 2021 financial results on Tuesday, November 9, 2021 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a business and pipeline update.